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Abstract
Diagnosis of liver cirrhosis is essential in the management of chronic hepatitis C virus (HCV) infection. Liver biopsy is invasive
and thus entails a risk of complications as well as a potential risk of sampling error. Therefore, non-invasive diagnostic tools
are preferential. The aim of the present study was to create a model for accurate prediction of liver cirrhosis based on
patient characteristics and biomarkers of liver fibrosis, including a panel of non-cholesterol sterols reflecting cholesterol
synthesis and absorption and secretion. We evaluated variables with potential predictive significance for liver fibrosis in 278
patients originally included in a multicenter phase III treatment trial for chronic HCV infection. A stepwise multivariate
logistic model selection was performed with liver cirrhosis, defined as Ishak fibrosis stage 5–6, as the outcome variable. A
new index, referred to as Nordic Liver Index (NoLI) in the paper, was based on the model: Log-odds (predicting cirrhosis) =2
12.17+ (age60.11) + (BMI (kg/m2)60.23) + (D7-lathosterol (mg/100 mg cholesterol)6(20.013)) + (Platelet count (x109/L)6(2
0.018)) + (Prothrombin-INR63.69). The area under the ROC curve (AUROC) for prediction of cirrhosis was 0.91 (95% CI 0.86–
0.96). The index was validated in a separate cohort of 83 patients and the AUROC for this cohort was similar (0.90; 95% CI:
0.82–0.98). In conclusion, the new index may complement other methods in diagnosing cirrhosis in patients with chronic
HCV infection.
Citation: Ydreborg M, Lisovskaja V, Lagging M, Brehm Christensen P, Langeland N, et al. (2014) A Novel Fibrosis Index Comprising a Non-Cholesterol Sterol
Accurately Predicts HCV-Related Liver Cirrhosis. PLoS ONE 9(4): e93601. doi:10.1371/journal.pone.0093601
Editor: Gulam Waris, Rosalind Franklin University of Medicine and Science, United States of America
Received October 5, 2013; Accepted March 5, 2014; Published April 3, 2014
Copyright:  2014 Ydreborg et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: ALF Funds at Sahlgrenska University Hospital and The Gothenburg Society of Medicine supported this study. Unrestricted grants from Roche affiliates
in the Nordic region and MSD Sweden also supported this study. The funders had no role in study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
Competing Interests: The authors hereby confirm that they did receive funding from Roche affiliates and MSD Sweden. This does not alter the authors’
adherence to all the PLOS ONE policies on sharing data and materials.
* E-mail: johan.westin@gu.se
. These authors contributed equally to this work.
Introduction
Morbidity and mortality in Hepatitis C virus (HCV) infection
results mainly from the development of complications of cirrhosis,
or hepatocellular carcinoma (HCC) [1]. Thus, the assessment of
liver fibrosis is of pivotal importance. Although the development of
new, highly efficacious treatment regimens will likely lessen the
significance of fibrosis staging for prognostication of treatment
outcome, it may remain central for tailoring of choice and
duration of therapy. Additionally, the diagnosis of cirrhosis will
continue to be vital to establish the need for HCC surveillance.
Liver biopsy remains the gold standard for the assessment of
liver fibrosis [2]. However, due to the potential risk of
complications [3] as well as other limitations, e.g. the risk of
sampling error and inter-observer variability [4,5] associated with
liver biopsy, several non-invasive methods for fibrosis assessment
previously have been proposed. Studies evaluating potential serum
biomarkers of fibrosis have been reported, either alone or
combined in indices [6–16]. Transient elastography has been
thoroughly evaluated among HCV infected patients [17–20] with
a high diagnostic accuracy for cirrhosis [21] but it may often be
difficult to obtain a valid examination, especially in obese patients.
In recent years algorithms combining different non-invasive
methods has improved the diagnostic accuracy for staging of
fibrosis [22,23]. For identification of cirrhosis, transient elasto-
graphy appears to be the most accurate method when compared
with currently available biomarkers [14,21], but a freely available
biochemical index that could complement to liver elastography
measurement for the diagnosis of cirrhosis is desirable.
Cholesterol synthesis is a process involving several steps.
Lathosterol and desmosterol are intermediates in the cholesterol
synthesis pathway and their serum concentration reflects choles-
terol synthesis ([24,25]. Sitosterol, avenasterol and campesterol are
plant sterols (phytosterols) derived from ingested food reflecting
intestinal absorption, while cholestanol is produced by enzymatic
cleavage of endogenous cholesterol. Cholestanol as well as plant
sterols reflects biliary secretion, and cholestanol is a marker of
chronic cholestasis [26,27]. In line with this, plasma levels of non-
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cholesterol sterols have been associated with either chronic
cholestasis or hepatocyte function, particularly in the setting of
primary biliary cirrhosis (PBC) [28]. Thus, it may be hypothesized
that concentrations of such non-cholesterol sterols potentially
could serve as biomarkers of disease progression, also in the
presence of HCV infection.
The aim of the present study thus was to evaluate a broad range
of non-invasive biomarkers for liver fibrosis, including a panel of
non-cholesterol sterols (cholestanol, desmosterol, lathosterol, sitos-
terol and campesterol) in order to create a predictive model for
HCV-related cirrhosis. This was done within the framework of a
phase III treatment trial, with a well-defined cohort of treatment-
naı¨ve patients and where pre-treatment liver biopsies were
mandatory.
Materials and Methods
Exploratory Set
The exploratory set cohort was derived from a phase III
multicenter, investigator initiated, treatment trial for treatment-
naı¨ve HCV genotype 2 or 3 infected patients (the NORDynamIC
study, n = 382) conducted at 31 centers in Denmark, Finland,
Norway and Sweden. Details regarding trial design and outcome
have been published previously [29]. The main outcome of the
trial was sustained viral response. Evaluation of biomarkers for
non-invasive diagnosis of cirrhosis was included among the
secondary aims of the trial in the study protocol. All patients
included were adults with detectable plasma HCV-RNA of
genotype 2 or 3 had compensated liver disease and were
seronegative for hepatitis B surface antigen and for antibodies to
human immunodeficiency virus (HIV). A liver biopsy within 24
months of entry was required. Body Mass Index (BMI kg/m2),
alcohol consumption during the previous year (g/week) and
duration of infection were recorded. Of the 382 patients enrolled,
298 patients had a liver biopsy that fulfilled the criteria for staging
and grading and had serum samples analyzed for potential fibrosis
markers in accordance with the study protocol. When all patients
with missing data in any of the parameters were excluded 278
patients remained. These patients constituted the exploratory set.
Table 1. Baseline characteristics in the (A) exploratory set and (B) the validation set according to presence of cirrhosis in liver
biopsy.
A. Exploratory set Cirrhosis Non cirrhosis P value
n = 36 n = 242
Sex female/male (%) 28/72 42/58 n.s
Age (years) 51(46–56) 41 (32–49) ,0.0001
BMI (kg/m2) 27 (24–32) 25 (22–28) 0.001
Duration of infection (years) 28.5 (20–35)a 11 (6–23)b ,0.0001
AST (/ULN) 2.05 (1.53–3.34) 1.23 (0.89–1.94) ,0.0001
ALT (/ULN) 2.32 (1.45–2.83) 1.43 (0.82–2.37) 0.001
Platelet count (109/L) 150 (97–206) 227 (196–266) ,0.0001
Prothrombin index INR 1.1 (1.0–1.2) 1.0 (1.0–1.1) ,0.0001
D7-lathosterol (mg/100 mg cholesterol) 97 (57–127) 118 (87–150) 0.008
Genotype 2/3 33/67 30/70 n.s
Ishak fibrosis stage 0/1/2/3/4 (%) 4/17/35/28/16 NA
Ishak fibrosis stage 5/6 (%) 42/58 NA
B. Validation set n = 8 n = 75
Sex female/male (%) 25/75 48/52 n.s
Age (years) 52(44–64) 51(44–55) n.s
BMI (kg/m2) 27 (25–29) 25(23–28) n.s
Duration of infection (years) 30(26–40)c 30(24–34)d n.s
AST (/ULN) 2.0(1.8– 3.0) 1.1 (0.9–1.8) 0.003
ALT (/ULN) 2.1(1.7–3.6) 1.1 (0.9–1.6) 0.001
Platelets (109/L) 141(109–213) 256(201–299) 0.001
Prothrombin-INR 1.1(1.0–1.2) 1.0(1.0–1.1) 0.02
D7-lathosterol (mg/100 mg cholesterol) 77(47–117) 117(85–155) 0.02
HCV genotype 1/2/3/4/mixed (%) 75/0/12.5/0/12.5 73/1/24/1/1 n.s
Ishak fibrosis stage 0/1/2/3/4 (%) 5/21/40/19/15 NA
Ishak fibrosis stage 5/6 (%) 38/62 NA
All values are presented as median (interquartile range; IQR) or percentage.
an = 28.
bn = 166.
cn = 6.
dn = 60.
doi:10.1371/journal.pone.0093601.t001
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Validation Set
The validation set was derived from a cohort of 100 chronic
HCV infected patients enrolled in a study evaluating the use of
liver biopsy, serum fibrosis markers and transient elastography by
use of the Fibroscan device [30], performed at the Department of
Infectious Diseases at Sahlgrenska University Hospital in Gothen-
burg in 2008–2010. All consecutive patients referred for a liver
biopsy during an eighteen months period were asked to
participate. Blood tests for analysis of serum fibrosis markers,
transient elastography examination and liver biopsy were
performed in the fasting state at the same day. All patients
included were HCV-RNA positive, HBsAg negative and anti-HIV
negative adults and had signed an informed consent.
Patients with missing data for any of the relevant parameters
were excluded from the present study, leaving 83 patients in the
validation set.
Ethical Considerations
Exploratory set. Written informed consent was obtained
from each participating patient. Ethics committees in each
participating country approved the study (i.e. Regional Ethical
Review Board, Gothenburg, Sweden (Regionala etikpro¨vnings-
na¨mnden i Go¨teborg), Regional Committee for Ethics in Medical
Research, Bergen, Norway (Regionaletisk komite for medisinsk og
helsefaglig forskning i Bergen), The Scientific Ethical Committee
for the Region of Middle Jutland, Viborg, Denmark (Den
Videnskabsetiske Komite´ for Region Midtjylland), The Scientific
Ethical Committee for the Region of South Denmark, Vejle,
Denmark (Den Videnskabsetiske Komite´ for Region Syddan-
mark), and the Ethics Committee, Department of Medicine for the
Hospital District of Helsinki and Uusimaa, Finland (Etiska
kommitte´n fo¨r inva¨rtesmedicin)). The study has been registered
at the NIH trial registry (ClinicalTrials.gov Identifier:
NCT00143000).
Validation set. Written informed consent was obtained from
each participating patient. The Regional Ethical Review Board,
Gothenburg, Sweden (Regionala etikpro¨vningsna¨mnden i Go¨te-
borg) approved the study.
Serum Markers
In the exploratory cohort, baseline serum samples were drawn
within 30 days prior to study entrance. Platelet count (x 109/L) and
Prothrombin complex-INR were analyzed at each center. All
other serum samples were stored in 270uC and subsequently
analyzed at a central laboratory at Helsinki University Hospital,
Finland. Liver function tests and serum fibrosis markers analyzed
by standard laboratory methods included normalized AST and
ALT, Gammaglutamyl-transferase (GGT) (U/L), Bilirubin (mmol/
L), Haptoglobin (g/L), alfa2-macroglobulin (g/L), Hyaluronic acid
(HA) (ng/ml), amino-terminal propeptide of type III procollagen
(PIIINP) (ug/L), Apolipoprotein A1 (g/L) and carboxy-terminal
telopeptide of type I collagen (ICTP) and serum cholesterol (mg/
100 ml). The non-cholesterol sterols (cholestanol, D8-lathosterol,
desmosterol, D7-lathosterol, campesterol, sitosterol, sitostanol,
avenasterol and squalene) were analyzed by gas–liquid chroma-
tography (GLC) (Agilent 6890N Network GC System, Agilent
Technologies Inc., Wilmington, DE) on a 50-m long Ultra 2
capillary column (5% Phenyl-methyl siloxane) (Agilent Technol-
ogies, Wilmington, DE, USA), with 5a-cholestane as internal
standard [31,32].
To correct for differences in serum levels of sterols as a
consequence of varying concentrations of lipoprotein particles, the
non-cholesterol sterol values are expressed as proportions of serum
Figure 1. Box-plots displaying the different components of the NoLI index (D7 lathosterol, platelet count, Prothrombin complex-
INR, age and BMI) and the NoLI index in relation to Ishak fibrosis stage.
doi:10.1371/journal.pone.0093601.g001
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cholesterol (mg/100 mg of cholesterol) as well as absolute
concentrations (mg/100 ml).
In the validation set all serum samples were drawn the same day
as the liver biopsy and immediately stored in 270uC. Serum
sterols were subsequently analyzed as stated above, all other
analyzes were performed according to routine laboratory proce-
dures at the Sahlgrenska University Hospital.
Histological Assessment
All liver biopsies in the exploratory and validation cohort were
retrieved and re-assessed for necroinflammatory activity and
fibrosis stage according to the Ishak protocol [33] by two
experienced observers in a dual observer consensus fashion as
previously described [29] where the two observers first indepen-
dently scored all biopsies. Potential topics of disagreement were
discussed, and a consensus score was agreed upon, which then was
used in the analysis. Steatosis was graded as absent (score of 0),
mild (score of 1, ,30% of the hepatocytes involved), moderate
(score of 2, 30–70%) or severe (score of 3, .70%) [34]. Biopsies
with a total length of ,15 mm or containing less than six portal
tracts were excluded. Cirrhosis was defined as Ishak fibrosis stage
5–6.
Statistical Analysis
The following variables were analyzed in the exploratory set:
age, sex, weight, BMI, genotype, platelets, PK-INR, normalized
Figure 2. Receiver operator characteristics curves plotting sensitivity against specificity for prediction of cirrhosis in the
exploratory set (n = 278) for the new index (NoLI) in comparison with some other biochemical indices. The AUROC for NoLI was 0.91
(95% CI 0.86–0.96). The corresponding AUROC for the other indices in the exploratory set were for FIB4 0.81 (95% CI 0.75–0.87), Lok 0.79 (95% CI 0.71–
0.87), APRI 0.81 (95% CI 0.74–0.88), and for GUCI 0.81 (95% CI 0.74–0.88).
doi:10.1371/journal.pone.0093601.g002
Table 2. Diagnostic accuracy for the proposed cut-off levels regarding the NoLI score for prediction of cirrhosis in 278 HCV-
infected patients.
Cut-off Sensitivity (%) Specificity (%) +LR 2LR NPV (%) PPV (%)
0.054 94(81–99) 68(62–74) 2.9(2.4–3.6) 0.08(0.02–0.32) 99(96–100) 30(22–40)
0.37 58(41–75) 95(92–97) 10.9(6.0–19.7) 0.44(0.30–0.65) 94(90–97) 62(44–78)
Abbreviations: +LR, positive likelihood ration; 2LR, negative likelihood ratio; NPV, negative predictive value; PPV, positive predictive value. All values are presented with
95% confidence interval.
doi:10.1371/journal.pone.0093601.t002
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AST and ALT, GGT, Bilirubin, Haptoglobin, alfa2-macroglob-
ulin, HA, PIIINP, Apolipoprotein A1, ICTP, total cholesterol,
cholestanol, D8-lathosterol, desmosterol, D7-lathosterol, campes-
terol, sitosterol, sitostanol, avenasterol and squalene. Classification
was made in two groups that encompassed fibrosis stages 0–4
(n = 242) and 5–6 (n = 36), respectively. The suggested classifica-
tion procedure consisted of two steps: (i) an index that resulted
from fitting of a model to the data and (ii) cut-off values for this
index that can be used to divide the predictions into two groups.
The data was modeled through logistic regression, with model
selection based on Akaike information criterion (AIC). The model
selection was done using goodness-of-fit criteria rather than the
magnitude of the p-values for each variable. The large number of
sometimes highly correlated factors leads to over fitting, i.e. a
model that was too large and sensitive to small perturbations in the
data. We decided to make the process of model selection more
robust by constructing logistic regression for a large number of re-
samples of the data and taking only those factors in the final index
that appeared in many of these, re-sampled models. The final
estimation of the coefficients was performed using the original
dataset. The new index based on the model above can be
formulated either in terms of probabilities (Iprob) or log-odds (Iodds),
which are equivalent. Iodds uses a more natural scale while Iprob
may be perceived as more intuitive since it reflects the probability
that a certain patient has cirrhosis. Iprob was chosen for further
calculations, hereafter referred to as the Nordic Liver Index, NoLI.
Cutoff values were chosen in order to minimize the misclassifica-
tion error. Rather than choosing one cut-off, we suggest applying
two, Clow and Chigh. If the index is below Clow, the observation will
be classified into group 1. If it is above Chigh it will be classified as
group 2. If between Clow and Chigh it will not be classified as either
Figure 3. Proportion of correct classifications (i.e. non-cirrhotic classified as non-cirrhotic and cirrhotic classified as cirrhotic)
according to different cut-off levels for NoLI. The solid vertical lines represent the chosen cut-offs 0.054 and 0.37. Using these cut-offs, the
misclassification error would be approximately 5% for cirrhotic as well as non-cirrhotic patients, respectively (dotted horizontal line).
doi:10.1371/journal.pone.0093601.g003
Figure 4. Scatter plot comparing the New index (NoLI) with
liver stiffness measured by transient elastography. The Spear-
man correlation coefficient was 0.542 (p,0.001).
doi:10.1371/journal.pone.0093601.g004
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group and further investigations may have to be undertaken to
make a correct diagnosis.
Diagnostic performance was analyzed by constructing receiver
operator characteristics curves (ROC) for specificity and sensitivity
with calculation of the area under the ROC curve (AUROC) and
the corresponding confidence interval (CI). The R software
package (Free software; www.r-project.org) version 2.15.0 was
used for all calculations and the package pROC was used to
calculate ROC curves and the corresponding CI. Comparisons of
baseline characteristics between groups were analyzed by Mann-
Whitney’s U test or Chi-squared test where appropriate.
Correlation between transient elastography and NoLI was assessed
by Spearman’s r test. These latter analyses were performed using
IBM SPSS Statistics version 19.0 software package (IBM
Corporation, Somers, NY). All reported p-values are two-sided,
and p-values ,0.05 were considered significant.
Results
Baseline Characteristics
Of the 278 patients included in the exploratory set, 36 (13%)
had cirrhosis; baseline characteristics for cirrhotic and non-
cirrhotic patients in the exploratory set are reported in Table 1A.
Of the 83 patients included in the validation set, 8 (10%) had
cirrhosis. Baseline characteristics are displayed in Table 1B.
There were no patients with clinically decompensated liver
cirrhosis in either exploratory or validation set. Patients in the
validation set were older than patients in the exploratory set;
median age was 49 (IQR 44–55) vs. 42 years (IQR 34–50) (p,
0.001), and had a longer duration of infection; 29 (IQR 24–34) vs.
13.5 years (IQR 6,8–25) (p,0.001) in the validation and
exploratory set respectively. In the exploratory set, 69% of the
patients were infected with HCV genotype 3, whereas in the
validation set HCV genotype 1 was most frequent, present in 72%
of patients.
Model for Prediction of Fibrosis
Application of the model selection methodology described
earlier lead to a final model comprising the following variables:
Age (p = 0.0002), BMI (p = 8.061025), D7-lathosterol (p = 0.02),
platelet count (p = 7.061025) and Prothrombin-INR (p = 0.122).
The model characteristics are summarized in table S1 and the
relation between each component of the index separately and
Ishak fibrosis stage is displayed in Figure 1. D7 lathosterol, was the
only sterol in the panel of sterols, which was independently
associated with cirrhosis.
The regression formula for this final model is: Log-odds; Iodds
(predicting cirrhosis) =212.17+ (age60.11) + (BMI (kg/m2)60.23)
+ (D7-lathosterol (mg/100 mg cholesterol)6(20.013)) + (Platelet
count (x109/L)6(20.018)) + (Prothrombin-INR63.69).
Predicted probability; Iprob = exp (log-odds)/(1+exp (log-odds)).
As stated above, we chose predicted probability (Iprob) for
further calculations, referred to as the Nordic Liver Index (NoLI).
The relation between NoLI and Ishak fibrosis stage is illustrated in
the lower right panel of Figure 1.
Area Under ROC (AUROC)
The ROC curve formed by plotting sensitivity against specificity
for the new index in prediction of cirrhosis in the exploratory set is
shown in Figure 2. The area under the ROC curve (AUROC) was
0.91 (95% CI 0.86–0.96). Figure 2 also displays ROC curves for
APRI [11], Lok index [10], GUCI [15] and FIB-4 [16]. Theses
indices were chosen for comparison since they are all freely
available non-invasive scores, evaluated and validated for the
detection of cirrhosis. The corresponding AUROC for the other
indices in the exploratory set were for FIB-4 0.81 (95% CI 0.75–
0.87), Lok index 0.79 (95% CI 0.71–0.87), APRI 0.81 (95% CI
0.74–0.88), and for GUCI 0.81 (95% CI 0.74–0.88).
Cutoff Values
Two cut-off values were chosen that would produce a minimal
misclassification error of approximately 5% for each group. Using
a predicted cut-off value of ,0.053 for the exclusion of cirrhosis
and .0.37 for the identification of cirrhosis would misclassify
5.6% (2/36) of patients with cirrhosis as non-cirrhotic and 5.0%
(12/242) of non-cirrhotic as having cirrhosis (with a cirrhosis
prevalence of 13%, a misclassification rate of 5.6% is the closest to
5% we can get). Figure 3 shows the proportion of correct
classifications for cirrhosis and non-cirrhosis according to different
cut-offs. The sensitivity, specificity, likelihood ratios and negative
and positive predictive values for the proposed cut-offs (0.053 and
0.37) are displayed in table 2. Among the 12 patients misclassified
as having cirrhosis, the Ishak fibrosis stages were distributed as
follows; F4 n = 7 (58%), F3 n = 3 (25%) and F2 n = 2 (17%). HCV
genotypes 2 and 3 were evenly distributed.
Validation Set
Applying the new index to the validation set, the AUROC for
prediction of cirrhosis was 0.90 (95% CI 0.83–0.98). In the
validation set, patients were also examined by transient elasto-
graphy. The Spearman correlation coefficient for the new index
and liver stiffness values was 0.54 (p,0.001; Figure 4). One patient
(a 66 year-old genotype-1-infected male with compensated
cirrhosis and mild steatosis) with a liver stiffness value of 50 kPa
was included in the calculation but not in the figure. To evaluate
the diagnostic capability of the new index using transient
elastography as reference, we used a cut-off of 12.5 kPa for
cirrhosis [17]. The resulting Roc-curve had an AUROC for
prediction of cirrhosis of 0.95 (95% CI 0.89–1.0).
Since the exploratory set included only patients infected with
HCV genotypes 2 and 3 and the validation set mainly genotype 1
infected patients, we combined the exploratory and validation set
to evaluate potential genotypic differences. No significant differ-
ences were detected and the AUROC for specificity vs. sensitivity
for each genotype was 0.91 (95% CI 0.82–1.0), 0.86 (95% CI
0.73–0.98) and 0.93 (95% CI 0.88–0.97) for genotypes 1, 2, and 3
respectively.
Discussion
The primary aim of this study was to develop a reliable model
for predicting HCV-related liver cirrhosis. The model created
could confidently predict cirrhosis in both the exploratory and the
validation sets, although the findings need to be confirmed in
larger series. Although there is considerable overlap between
adjacent fibrosis stages, this model has a good ability to exclude
cirrhosis in patients with less severe stages of fibrosis (Ishak F0-4) as
well as to predict cirrhosis in biopsy-verified cirrhotic patients
(Ishak F5-6). Like many other biochemical indices, NoLI performs
better in excluding than confirming cirrhosis.
The new index combines age, BMI, platelet count and
prothrombin index, i.e. factors that previously have been
consistently associated with fibrosis [6,9–11,35], along with D7-
lathosterol which, to our knowledge, has not previously been
evaluated in this setting. Serum D7-lathosterol is a precursor of
cholesterol and its plasma concentration reflects cholesterol
synthesis and correlates with 5-alfa-HMG-reductase activity, the
rate-limiting enzyme of cholesterol synthesis [24,25]. With the
New Fibrosis Index Predicts HCV Cirrhosis
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development of liver cirrhosis, the synthetic function in the liver,
including cholesterol synthesis, decreases [36]. Thus, it is plausible
that the concentration of D7-lathosterol in serum would reflect
liver function and that decreased levels of lathosterol could be an
early sign of advanced liver fibrosis. On the other hand, the sterols
primarily reflecting cholestasis did not predict cirrhosis in this
setting, which is not surprising since cholestasis is not a common
feature in HCV-related cirrhosis. Accordingly, none of the
cirrhotics in any of the sets cohorts had elevated serum-bilirubin
levels indicating cholestasis. The hepatitis C virus is known to
interfere with host lipid metabolism resulting in reduced levels of s-
cholesterol and hepatic steatosis [37] that resolves following
successful antiviral treatment, at least in genotype 3 infected
patients [38,39]. In non-genotype 3 patients, however, steatosis
has been associated with insulin resistance and the metabolic
syndrome [40,41]. In a recent study, Clark et al [42] demonstrated
that HCV genotype 3, but not genotype 2, interferes with the
distal cholesterol pathway, which resolves after successful antiviral
treatment. In the same study, no significant differences in the levels
of lathosterol was found between genotype 2 and 3 infected
patients suggesting that this genotype-specific interaction occurs
further down in the pathway. The evaluation of NoLI index
according to HCV genotype in the present study showed no
statistically significant differences regarding AUROC between
genotypes and the level of serum lathosterol does not seem to be
genotype-dependent in this setting.
Several studies on the prediction of cirrhosis have been reported
during the past 10 years [7,10–13,15,16,43–45]. In a large
multicenter study by Degos et al [14] evaluating the diagnostic
accuracy of Fibroscan and FibroMeter, FibroTest, APRI and
Hepascore for the prediction of cirrhosis, AUROC ranged from
0.77 to 0.86. FibroMeter [7], FibroTest [14] and Hepascore [12]
are all validated and frequently used for the prediction of cirrhosis
but they are all protected by patented formula making them less
accessible. The AST-to-platelet ratio index (APRI) [11] as well as
the Lok-index [10] and FIB-4 [16] are all free of cost and based on
routine laboratory parameters making them easy to use in routine
clinical practice. When compared in the exploratory set, our
model performed slightly superior to these other non-patented
scores. Unfortunately, the size of and cirrhosis prevalence in the
validation set did not allow for in-depth comparison.
Our study had some potential limitations. Measurement of
serum lathosterol is not a standard biochemical test. Although it is
measured using gas-chromatography standard patent-free labora-
tory technique, commonly used for analysis of other compounds, it
may be slightly cumbersome to use. Still, the presence of D7-
lathosterol improves the diagnostic performance of the NoLI index
why we choose to keep it in the model.
The prevalence of cirrhosis in the exploratory and validation
sets was 13% and 10% respectively, which is low compared with
some other studies on non-invasive fibrosis markers using liver
biopsy as reference [10,21]. This lessens the ability to create a solid
model for prediction. However, a cirrhosis prevalence of around
15% seems to be common in unselected Hepatitis C populations
[14,46]. The limited sample size and the low prevalence of
cirrhosis in the validation set is a major limitation and does not
permit accurate comparison between different indices, and the
diagnostic performance of the new index need to be tested also in
other larger cohorts. Moreover, other studies of fibrosis markers
have been validated in cohorts of similar size, e.g. AST to platelet
ratio index (APRI), a very reliable and widespread fibrosis index,
was created in an exploratory set of 192 patients (15 (16%)
cirrhotics) and validated in a cohort of 78 subjects (13 (17%)
cirrhotics) [11]. The patients in the validation set were recruited
from a group of consecutive patients referred for routine liver
biopsy and were thus potential candidates for non-invasive fibrosis
assessment in clinical practice. The patients in the exploratory and
validation sets differed regarding HCV genotypes as well as
country of residency, although none of these factors were
independently associated with cirrhosis when patients in the two
sets were analyzed together (cirrhosis was more common in
Sweden and Denmark which was due to an age effect, data not
shown). Thus they would not have influenced the statistical model.
In the exploratory set, liver biopsies and serum samples were not
taken at the same time point, although both were sampled prior to
initiation of therapy. The index, however, performed well in the
validation set where blood samples were drawn on the day of the
liver biopsy. As with all non-invasive tests, the use of liver biopsy as
comparison poses a problem since liver biopsy is prone to sampling
error and thus can both over- and underestimate the true liver
fibrosis stage [4]. As shown by Bedossa et al only 65% of biopsies
relying on 15-mm samples led to correct diagnosis using
METAVIR scoring system [5]. Hence, the absolute correctness
of a non-invasive fibrosis marker would need to be estimated by
use of other methods. Potential exclusion of cirrhotic patients due
to a greater tendency towards inadequate biopsy size may have
introduced a bias in the exploratory set. However, contrary to this
notion, non-invasive markers (GUCI and APRI) did not differ
significantly among excluded (n = 27) vs. included patients
(p = 0.3). Although not the primary aim of this study, it is still
interesting to note that the concordance of this index with
Transient Elastography might be greater than with liver biopsy
(AUC 0.95 (95% CI 0.89–1,0) vs. 0.90 (95% CI 0.83–0.98).
Another perhaps more appropriate endpoint to use as gold
standard would be the risk of liver related complications or death
over time but that would be beyond the scope of the present study.
A liver biopsy can provide much more pertinent information than
serologic fibrosis markers on liver histology and may remain of
importance in some cases in the future. However, we believe that
serologic markers should be considered an important complement
to liver biopsy.
In summary, our results indicate that an index combining well-
known predictors of liver fibrosis in combination with measure-
ment of a non-cholesterol sterol can be useful in predicting
cirrhosis. These new findings could be of value as a supplement to
already existing non-invasive methods and the application of our
model potentially could aid clinical decision-making, e.g. on which
patients require continued monitoring in spite of successful
antiviral treatment.
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